Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Silvija Kraljevic | Researchclopedia

Back to researchers

Silvija Kraljevic

AstraZeneca (United Kingdom)ORCID

29

Works

5,741

Citations

9

h-index

8

i10-index

Research Topics

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Cancer Genomics and Diagnostics

Affiliations

AstraZeneca (United Kingdom)2021–2025

Hospital Clínico Universitario de Valencia2009–2009

Eisai (United Kingdom)2017–2019

Top Works

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo,Richard S. Finn,et al.

20185,313 citations

Hepatocellular Carcinoma Treatment and Prognosis

Colorectal Cancer Treatments and Studies

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Masafumi Ikeda,Max W. Sung,et al.

2018124 citations

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Ann‐Lii Cheng,Richard S. Finn,et al.

201787 citations

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Helena A. Yu,Sarah B. Goldberg,et al.

202167 citations

1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

Helena A. Yu,Helen Ambrose,et al.

202146 citations

Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).

Nathalie Gaspar,Michela Casanova,et al.

201830 citations

Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma

T.R. Jeffry Evans,Masatoshi Kudo,et al.

201928 citations

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors

Josep Tabernero,Luc Dirix,et al.

200918 citations

Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA).

Jan A. Burger,Paolo Ghia,et al.

20139 citations